Engineered immune cells take aim at a common pancreatic cancer mutation

NCT ID NCT07649928

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests an experimental drug called ES502 in people with advanced pancreatic cancer that has a specific genetic change (RAS G12V) and who have run out of standard treatments. ES502 is a lab-made protein designed to guide the body's immune T-cells to attack cancer cells carrying that mutation. The study's main goals are to check the drug's safety and find the best dose, while also watching for any signs that tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ES502 injection (a bispecific T-cell receptor fusion protein targeting RAS G12V)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced pancreatic cancer who have the RAS G12V mutation and no other options.
What could go wrong: This is a very early, small study (24 people) focused on safety. The treatment may not shrink tumors or could cause serious side effects. Success in this phase does not guarantee broader benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.